SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
MALVERN, Pa., Feb. 23, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its fourth quarter financial results before the market opens on March 15, 2017
Management will conduct a conference call at 8:00 a.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 62366728 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
